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Fracture Related Issues
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Abstract
Canadian guidelines recommend either the FRAX or the Canadian Association of Radiologists and Osteoporosis
Canada (CAROC) fracture risk assessment tools to report 10-yr fracture risk as low (!10%), moderate (10%e20%)
or high (O20%). It is unknown whether one reporting system is more effective in helping family physicians (FPs)
identify individuals who require treatment. Individuals 50 yr old with a distal radius fracture and no previous osteoporosis diagnosis or treatment were recruited. Participants underwent a dual-energy x-ray absorptiometry scan
and answered questions about fracture risk factors. Participants’ FPs were randomized to receive either a FRAX report or the standard CAROC-derived bone mineral density report currently used by the institution. Only the FRAX
report included statements regarding treatment recommendations. Within 3 mo, all participants were asked about
follow-up care by their FP, and treatment recommendations were compared with an osteoporosis specialist. Sixty
participants were enrolled (31 to FRAX and 29 to CAROC). Kappa statistics of agreement in treatment recommendation were 0.64 for FRAX and 0.32 for bone mineral density. The FRAX report was preferred by FPs and resulted
in better postfracture follow-up and treatment that agreed more closely with a specialist. Either the clear statement of
fracture risk or the specific statement of treatment recommendations on the FRAX report may have supported FPs to
make better treatment decisions.
Key Words: Bone mineral density; decision making; fracture risk; FRAX; osteoporosis; treatment
recommendation.

(7e9) and medications reduce the risk of fractures by 40%
e70% (10e12). A significant care gap exists between the
number of individuals who should be treated for osteoporosis
and those who receive treatment (5,6,13e15), reinforcing the
need for the application of clinical guidelines (16,17). Barriers to the adaptation of guidelines include a lack of knowledge about risk factors and the interpretation of bone mineral
density (BMD) results (18e22).
The World Health Organization’s fracture risk assessment
tool (FRAX) (23) and the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) (3) fracture risk assessment tool improve the identification of patients who

Introduction
Despite guidelines for diagnosing and managing osteoporosis (1e3), few individuals who experience a fragility fracture are evaluated for osteoporosis, and even fewer are
treated (4e6). This is concerning because experiencing a fracture after age 50 yr is a major risk factor for future fractures
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would benefit from treatment by categorizing them as having
a low (!10%), moderate (10%e20%), or high (O20%) fracture risk over 10 yr. These tools, both of which are used in
Canada (1), integrate clinical risk factors for fracture with
BMD. Accordingly, they improve the sensitivity and specificity of fracture prediction (24e26). Clinical risk factors included in FRAX are age, previous fragility fracture,
parental history of hip fracture, smoking status, high alcohol
intake, systemic use of corticosteroids, low body mass index,
and diseases associated with secondary osteoporosis (26e29).
The CAROC tool includes sex, age, and femoral neck BMD
with prevalent fragility fractures and corticosteroid incorporated as step-wise categorical modifiers of baseline fracture
risk. The FRAX tool estimates precise risk of a major osteoporotic fracture (in percent), whereas the CAROC tool confers only categorical risk.
Controlled trials have assessed whether changes in knowledge translation about osteoporosis guidelines and fracture
risk factors result in more appropriate treatment (14,30,31).
In one study, authors recommended future studies improve
the treatment rate by using ‘‘more clinically useful and directive density reports’’ (14). Another study suggested that, in
terms of clinical decision-making, the structure of BMD reporting may be as important as the accuracy of BMD measurements (32).
We attempted to close the care gap by testing whether the
implementation of a FRAX report would assist family physicians (FPs) in identifying patients who would benefit from
treatment. Compared with a standard CAROC-generated
BMD report, we hypothesized that a FRAX report would
better convey fracture risk to FPs thereby improving the treatment rate of patients at high fracture risk.

Materials and Methods
Individuals 50 years treated at the Hand and Upper Limb
Center (HULC, London, ON) within 1 month of sustaining
a fragility fracture of the distal radius were enrolled. Individuals were excluded if they (1) had previously been diagnosed
with osteoporosis, (2) were currently taking osteoporosis
medications, (3) did not have an FP, or (4) were unable/unwilling to provide informed consent. Participants completed
the Self-Administered Comorbidity Questionnaire (33) and
the International Osteoporosis Foundation Risk Test (34) before undergoing bone densitometry (GE Lunar Prodigy Advance system, GE Healthcare, Madison, WI). Participants’
FPs were randomly allocated to receive either a standard
CAROC-based BMD report used at this center (hereafter referred to as the standard BMD report) or a customized report
based on the FRAX model (hereafter referred to as the FRAX
report). All reports were generated by a single physician
(A.B.H.), who was not blinded to group allocation. Group allocation was concealed to the remaining study investigators.
FPs were not aware their patients were participating, and neither participants nor FPs were aware of the study’s primary
outcome. Individuals whose FP had already been entered
into the study through a previous participant were excluded.
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Standard BMD reports (Appendix 1) included participants’
femoral neck and lumbar spine BMDs and T-scores. Fracture
risk category was determined with the CAROC tool; the wrist
fracture increased the baseline risk category into the next
highest category (1). The report categorized the participant
as low, moderate, or high fracture risk. The FRAX report
(Appendix 2) used participants’ femoral neck BMD and clinical risk factors incorporated by the FRAX tool; Canadian
population data were used (35). The report indicated which
clinical risk factor(s) were present and the percent probability
of a major osteoporotic fracture over the next 10 yr. The
FRAX report highlighted the fracture risk category and included statements regarding treatment recommendations as
per clinical guidelines (1). Before the study, feedback received from 8 nonparticipating FPs regarding the layout and
content of the FRAX was used to inform the revised FRAX
report used in the study. Study participants did not receive
a copy of their fracture risk report. Three months after reports
were sent to FPs, participants were called and asked a series
of questions regarding follow-up by their FP including
whether the participant had been contacted by their FP,
whether the FP discussed their results with them, and whether
they were recommended for treatment. Participants who
could not be reached at 3 months received a second followup phone call 1 month later.
To determine if FPs follow-up (i.e., treatment recommendation or not) was appropriate, all reports were read by an
osteoporosis specialist (J.D.A.) who was considered the reference for comparison. Only information on the report was
available to the specialist, who was blinded to treatment decisions made by FPs.
To confirm participants’ responses regarding follow-up
care, we attempted to contact FPs. A questionnaire was sent
to each FP to confirm participants’ responses regarding
follow-up care and to corroborate information regarding treatment. An additional questionnaire was distributed to FPs allocated to the FRAX report group to survey their understanding
and preference for the FRAX report over the standard BMD
report. FPs who responded received a gift card in appreciation
of their time. The study was approved by the Research Ethics
Boards at McMaster University Faculty of Health Sciences/
Hamilton Health Sciences and the University of Western
Ontario.

Statistical Analyses
Descriptive statistics were conducted to characterize the
study population. Kappa statistics and 95% confidence intervals (CIs) were calculated to determine agreement between
FPs’ treatment decisions compared with those of the osteoporosis specialist. A Fisher’s exact test was used to compare the
differences between the treatment rates in the 2 groups and
whether there was a significant difference in the number of
FPs’ discussion with patients between the standard BMD
report group and the FRAX group. Participants’ responses
regarding the follow-up they received from their FPs are summarized as are the questionnaire responses from FPs regarding their feedback on the FRAX reports.
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Table 1
Descriptive Statistics for the Study Population

Variable
Age, yr
BMI, kg/m2
Femoral neck BMD, g/cm2
Lumbar spine BMD, g/cm2
Femoral neck T-score
Lumbar spine T-score
Female
Current smoker
Family history of osteoporosis
Heart disease
High blood pressure
Lung disease
Diabetes
Ulcer/stomach disease
Anemia/blood disease
Cancer
Depression
OA/degenerative arthritis
Back pain
Rheumatoid arthritis

Entire group (n 5 60)
Mean (SD)/n (%)
65.0
27.0
0.86
1.14
1.12
0.56
49
7
18
5
21
2
3
5
2
6
10
15
21
3

(9.5)
(5.4)
(0.11)
(0.20)
(0.91)
(1.66)
(81.7)
(11.7)
(30.0)
(8.3)
(35.0)
(3.3)
(5.0)
(8.3)
(3.3)
(10.0)
(16.7)
(25.0)
(35.0)
(5.0)

Standard BMD (n 5 29)
Mean (SD)/n (%)
65.3
27.3
0.87
1.13
1.03
0.61
24
2
7/28
2/29
11/29
1/29
1/29
2/29
1/29
1/29
4/29
7/29
9/29
2/28

(9.4)
(5.7)
(0.10)
(0.15)
(0.91)
(1.30)
(86.2)
(6.9)
(25)
(6.9)
(37.9)
(3.4)
(3.4)
(6.9)
(3.4)
(3.4)
(13.8)
(24.1)
(31.0)
(7.1)

FRAX (n 5 31)
Mean (SD)/n (%)
64.7
26.8
0.85
1.14
1.20
0.51
24
5
11/30
3/31
10/31
1/31
2/31
3/31
1/31
5/30
6/31
8/31
12/30
1/31

(9.7)
(5.1)
(0.12)
(0.24)
(0.93)
(1.96)
(77.4)
(16.1)
(36.7)
(9.7)
(32.3)
(3.2)
(6.5)
(9.7)
(3.2)
(16.7)
(19.4)
(25.8)
(40.0)
(3.2)

Abbr: BMD, bone mineral density; FRAX, fracture risk assessment tool; OA, osteoarthritis.

Results
Participants’ demographic information (mean [SD] age
65  9.5 yr, 82% women) is shown (Table 1). Randomization
resulted in the allocation of 29 FPs to receive a standard BMD
report and 31 FPs to receive an FRAX report. In the standard
BMD report group, 20 participants were at moderate fracture
risk whereas 9 were at high risk. In the FRAX report group,
11 were at low fracture risk, 16 at moderate risk, and 4 at
high risk.
In following up with study participants in the standard
BMD report group, 8 of 29 (27.6%) reported being contacted
by their FPs (5 moderate, 3 high) whereas 14 of 29 (45.6%; 9
moderate risk, 5 high risk) reported discussing their results
with their FP. In the FRAX report group, 14 of 31 (45.2%)
participants were contacted by their FP (5 low, 6 moderate,
3 high) whereas 20 of 31 (64.5%) participants (7 low, 10 moderate, 3 high) reported discussing their results with their FP.
Although a 19% greater rate of discussion with FPs that occurred in the FRAX group may be clinically relevant, this difference was not statistically significant ( p 5 0.29). Five
participants in each group reported being recommended for
pharmacologic therapy (Table 2). One of the 2 additional
high-risk participants in the FRAX group was not followedup by her FP even 4 months after BMD testing, and one
was not treated despite discussing her results with her FP.
In the standard BMD report group, 15 of 29 (51.7%) FPs
were successfully contacted to corroborate their patients’

responses compared with 20 of 31 (64.5%) in the FRAX
group. In all cases, FPs’ responses were consistent with participants regarding follow-up care. In comparing treatment
decisions made by the FPs with those of an independent,
blinded osteoporosis specialist, FPs recommended treatment
in 5 patients allocated to the standard BMD group, compared
with 8 patients recommended by the specialist. Only 3 of
these participants were recommended for treatment by both
Table 2
The Number and Proportion (%) of Participants
Recommended for Pharmacologic Therapy by Their
Family Physicians and the Osteoporosis Specialist

Standard BMD
Moderate
High
FRAX
Low
Moderate
High

Number treated (%)
by family physician

Number treated (%)
by osteoporosis
specialist

1/20 (5.0)
4/9 (44.4)

0/20 (0)
8/9 (88.9)

0/11 (0)
3/16 (18.9)
2/4 (50.0)

0/11 (0)
5/16 (31.3)
4/4 (100.0)

Abbr: BMD, bone mineral disease; FRAX, fracture risk assessment tool.
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Fig. 1. Summary of family physicians’ responses to questions regarding their understanding and preference for FRAX reports
compared with standard BMD reports. ‘‘Agree’’ responses are a composite of those who responded to strongly agree, moderately
agree, and mildly agree. Responses of strongly, moderately and mildly disagree are represented by ‘‘Disagree.’’ BMD, bone
mineral disease; FRAX, fracture risk assessment tool.
the physicians yielding an overall kappa statistic of agreement
of 0.32 (95% CI 0.00e0.70). In the FRAX group, FPs recommended treatment for 5 patients compared with 9 by the specialist. All 5 patients treated by the FPs also were treated by
the specialist, yielding an overall kappa statistic of 0.64 (95%
CI 0.33e0.95). No participants at low risk were recommended for treatment by either the physician.
Nineteen of 31 FPs (61.2%) who received FRAX reports
responded to questionnaires regarding their understanding
and preference for the FRAX reports vs the standard BMD reports. Answers were given on a 7-point Likert scale ranging
from ‘‘strongly disagree’’ to ‘‘strongly agree.’’ Feedback regarding these reports was generally positive (Fig. 1).

Discussion
This study evaluated the outcomes of care provided by FPs
to their patients after routine treatment for a wrist fracture.
There was a greater rate of treatment (44% vs 50%) in
high-risk participants whose FPs received the FRAX report.
Agreement between the osteoporosis specialist and the FPs’
treatment recommendations also was higher for the FRAX
report. Compared with standard CAROC-based BMD reports
FPs routinely received from the center, which made no directive treatment recommendations, FPs who received the FRAX
report understood the report, found it easier to explain to their
patients, and agreed that it simplified their treatment decision.
Currently, Canadian guidelines (1) recommend that individuals at high fracture risk be treated; those at moderate
risk (10%e20%) should at least be considered for pharmacotherapy if other risk factors coexist, and those at low fracture
risk (!10%) should not be treated. These categories provide
a pathway to evaluate treatment decisions following bone
densitometry. Approximately 3 months after enrollment,
28% of participants in the standard BMD group had been contacted by their FPs, and 46% had discussed their results with

their FPs. The difference in these figures might result from
patients visiting their FPs as a follow-up to their fracture or
regarding a different concern, yet discussed the results of their
BMD report. However, only 3 of 9 participants at high fracture risk, when the standard BMD report was used, discussed
their results with their FPs.
For participants allocated to the FRAX report group, outcomes were more consistent. Here, 45% of participants
were contacted by their FPs and 65% discussed their results.
Some discussion of the FRAX report took place across all
levels of fracture risk; 64% at low risk, 38% at moderate
risk, and 75% at high risk discussed their results with their
FP. Although differences in frequencies of discussions with
patients between groups were not statistically significant,
the FRAX report appears to have triggered a more clinically
consistent response, which is encouraging and worth exploring in a larger prospective study.
The FRAX tool was developed as a means of estimating
absolute fracture risk thereby simplifying treatment decisions
by establishing country-specific fracture risk treatment
thresholds. Overall, there was a clinically greater degree of
agreement of treatment recommendations with the specialist
with FPs who received the FRAX report compared with the
standard BMD report. Given all participants had a fragility
fracture, no participants in the standard BMD group were at
low fracture risk. Therefore, all participants would be at least
considered for treatment by the FP. Only 4 of 9 participants
(44%) allocated to the standard BMD report were recommended for treatment by their FPs, which is concerning given that
guidelines recommend individuals at high fracture risk be
treated. In the FRAX group, none of the 11 participants at
low fracture risk were treated. Comparatively, although only
half of the high-risk patients assessed by FRAX were treated
pharmacologically (2/4), results were at least discussed by
a third patient. Small numbers of individuals in the highfracture risk groups make it difficult to conclude that high
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fracture risk patients were treated more appropriately by FPs
who received the FRAX report.
Treatment recommendations for patients at moderate fracture risk remain problematic (36) because either treatment or
no treatment might be appropriate depending on individual
circumstances. The specialist was less likely to recommend
treatment for patients at the lower end of ‘‘moderate risk’’
(e.g., 11%e13%) than the higher end (e.g., 17%e19%). Unlike the CAROC tool, which provides categorical risk, the
FRAX report facilitates this approach by providing a point estimate of risk. Only 1 of 20 participants at moderate risk in
the standard BMD report group was recommended for treatment by her FP. The specialist did not recommend treatment
in this participant. Of the 16 patients at moderate risk by the
FRAX report, the specialist would have treated 5. The FPs
discussed the FRAX reports with all 5 of these participants,
and 3 were treated.
No other studies have prospectively assessed the effects
of an FRAX report on treatment behavior of physicians,
although 3 retrospective studies have been conducted
(32,36,37). Two studies compared physicians’ prescribing behaviors between a period before the introduction of absolute
fracture risk reporting compared with afterward. In one study,
conducted only in osteopenic individuals (O83% male), investigators concluded that the inclusion of FRAX in a bone
density report had no effect on physicans’ prescribing behavior (36). However, this study included a predominantly male
population, and the lack of knowledge about FRAX may have
led physicians not to consider this information in their decision making. In contrast, Leslie et al (32) concluded that
the transition from a T-score based fracture risk report to a report based on absolute fracture risk resulted in appropriate,
guideline-based changes in pharmacological treatment. This
was based on fewer lower- and moderate-risk patients being
treated with the absolute fracture risk reporting system. These
observations are consistent with our results, in which 11 participants at low fracture risk in the FRAX group would not
be treated. The third study investigated agreement between
rheumatologists on whether to treat a patient after reading
a T-score based report compared with an absolute fracture
risk report. A greater agreement was observed after reading
absolute fracture risk reports, resulting in improved consistency and perhaps efficiency in treating patients (37).
Feedback from FPs regarding the FRAX report was
positive. Of all respondents (62%), FRAX reports were well
understood and aided in simplifying treatment decision making (Fig. 1). These results are consistent with previous studies
(37,38). However, it is not clear whether the FRAX report itself or the accompanying evidence-based guidelines on treatment according to fracture risk category influenced FP
treatment decisions.
This study suffers from several limitations. There were too
few participants at moderate or high fracture risk to determine
whether the FRAX report group had a significantly improved
treatment rate. Although the FRAX report contained a point
estimate of fracture risk, emphasized risk categorization,
and structured evidence-based treatment recommendations
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in accordance with the risk category, the routinely used
CAROC-based standard report provided only the risk category without treatment recommendation. Thus, it is not possible to isolate the particular components of the report that
influenced treatment outcomes. Thus, we cannot speculate
whether an optimized CAROC-based report would have affected treatment outcomes. However, as previously shown
(32), our results suggest that the CAROC-based report leads
to systematic overtreatment of patients with wrist fractures.
We did not evaluate the potential additional impact that giving copies of the fracture risk report to patients may have
had on treatment recommendations by the FP. In addition,
only 58% of FPs returned requests to corroborate their study
participants’ responses. Although there was complete agreement among respondents, we cannot generalize this to the remaining cases.
In summary, a greater proportion of FPs who received
a FRAX report contacted their patients and discussed the
test implications compared with FPs who received the standard BMD report. There was greater agreement in treatment
outcomes between the osteoporosis specialist and FPs who
received the FRAX report than the standard BMD report. Despite few participants at high fracture risk, there was a greater
treatment rate of participants whose FPs received the FRAX
report. If these results can be repeated in a larger study
population, the use of a more appropriately structured
BMD report based on the FRAX tool coupled with simple
evidence-based treatment recommendations has the potential
to reduce the existing treatment care gap following a wrist
fracture.
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Appendix 1. An Example of a Standard BMD Report Yielded Using CAROC Guidelines

PIN:
Patient Name:
DOB: Dec. 28, 1944
Age: 68 yrs
Attending Dr: Orthopedic Surgeon Name

This Report For: Family Physician Name

Consultation Report
Exam Date/Time
Oct. 11, 2011

Exam Type
Bone Mineral Density

Ordering MD
Orthopedic Surgeon Name

Accession #
Study ID #

Clinical History Provided by Referring Service: Recent wrist fracture

2

Lumbar Spine: BMD of the region of L2-L4 is 1.160 gm/cm . T score is -0.3 (comparison in standard
deviations to normal peak bone mass). Z score is +1.3.
INTERPRETATION: Osteopenia
2

BMD of the proximal femur (total) is 0.828 gm/cm . T score is -1.4. Z score is -0.2.
INTERPRETATION: Osteopenia
Fracture risk is increased approximately 2 times for each standard deviation below peak bone mass, as
shown by the T value.
Z score indicates the number of standard deviations patient density lies in comparison to an age and sex
matched control group.
From the lowest T-score, the 10 yr probability of further osteoporotic fracture is Moderate (10-20%).
This study was done on the Hand and Upper Limb research scanner (GE Lunar).
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Appendix 2. An Example of a FRAX Report

1

Female NHANES 3 reference range used for both men and women, irrespective of race.
If L-spine degenerative changes (qualitative assessment of osteophytes, degenerative disk disease) are significant,
result should not be used for diagnosis or serial monitoring. The spine is no longer recommended for diagnostic
categorization, but is more sensitive to monitoring changes in response to therapy.
3
Estimates assume the patient is treatment-naive; ongoing therapy will reduce the future risk.
4
Papaioannou A, Morin S, Cheung AM, et al; Scientific Advisory Council of Osteoporosis Canada. 2010 2010 clinical
practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182:1864-1873.
2
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